Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Update

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 22,360,000 shares, a growth of 41.5% from the January 15th total of 15,800,000 shares. Based on an average trading volume of 11,370,000 shares, the short-interest ratio is currently 2.0 days.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent research reports. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. UBS Group lowered their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. JPMorgan Chase & Co. raised their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, Barclays lowered their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $23.57.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA traded down $0.40 during midday trading on Friday, reaching $16.24. The stock had a trading volume of 12,463,268 shares, compared to its average volume of 13,828,842. The firm’s 50 day moving average price is $19.96 and its 200-day moving average price is $18.51. Teva Pharmaceutical Industries has a 52 week low of $12.51 and a 52 week high of $22.80. The company has a market capitalization of $18.39 billion, a P/E ratio of -11.20, a P/E/G ratio of 1.39 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.61.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. On average, analysts forecast that Teva Pharmaceutical Industries will post 2.62 earnings per share for the current fiscal year.

Insider Activity at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares of the company’s stock, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several large investors have recently modified their holdings of the stock. Ion Asset Management Ltd. increased its stake in Teva Pharmaceutical Industries by 1.1% in the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock worth $807,766,000 after purchasing an additional 409,778 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Teva Pharmaceutical Industries by 69.0% in the fourth quarter. Northern Trust Corp now owns 5,206,360 shares of the company’s stock worth $114,748,000 after buying an additional 2,125,266 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Teva Pharmaceutical Industries by 18.7% in the fourth quarter. The Manufacturers Life Insurance Company now owns 513,328 shares of the company’s stock worth $11,314,000 after acquiring an additional 80,926 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $44,000. Finally, Capital Analysts LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $102,000. 54.05% of the stock is owned by institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.